Criminal or bystander: imatinib and second primary malignancy in GIST patients

被引：8
|
作者：
Kanda, Tatsuo [1 ]
机构：
[1] Sanjo Gen Hosp, Sanjo City, Niigata 9550055, Japan
来源：
CHINESE JOURNAL OF CANCER RESEARCH | 2013年 / 25卷 / 05期
关键词：
GASTROINTESTINAL STROMAL TUMORS; NEOPLASMS; COEXISTENCE; KIT;
D O I：
10.3978/j.issn.1000-9604.2013.10.15
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：490 / 492
页数：3
相关论文
共 50 条
  • [41] Continuation therapy with the tyrosine kinase inhibitor Imatinib for patients with advanced GIST
    Oechsle, K.
    Bokemeyer, C.
    ONKOLOGE, 2007, 13 (08): : 743 - 744
  • [42] Sunitinib treatment in pediatric patients with metastatic GIST following failure of imatinib
    Janeway, K.
    Matthews, D.
    Butrynski, J.
    D'Amato, G.
    Agresta, S.
    Garrett, C.
    Corless, C.
    Albritton, K.
    Demetri, G.
    ANNALS OF ONCOLOGY, 2006, 17 : 102 - 102
  • [43] Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients
    Schiavon, Gaia
    Ruggiero, Alessandro
    Schoeffski, Patrick
    van der Holt, Bronno
    Bekers, Dave J.
    Eechoute, Karel
    Vandecaveye, Vincent
    Krestin, Gabriel P.
    Verweij, Jaap
    Sleijfer, Stefan
    Mathijssen, Ron H. J.
    PLOS ONE, 2012, 7 (11):
  • [44] Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?
    Zhuang, Wei
    Xie, Jing-Dun
    Zhou, Shan
    Zhou, Zhi-Wei
    Zhou, Yi
    Sun, Xiao-Wei
    Yuan, Xiu-Hong
    Huang, Min
    Liu, Si
    Xin, Shuang
    Su, Qi-Biao
    Qiu, Hai-Bo
    Wang, Xue-Ding
    CANCER MEDICINE, 2018, 7 (02): : 317 - 324
  • [45] Sunitinib Treatment in Pediatric Patients With Advanced GIST Following Failure of Imatinib
    Janeway, Katherine A.
    Albritton, Karen H.
    Van Den Abbeele, Annick D.
    D'Amato, Gina Z.
    Pedrazzoli, Paolo
    Siena, Salvatore
    Picus, Joel
    Butrynski, James E.
    Schlemmer, Marcus
    Heinrich, Michael C.
    Demetri, George D.
    PEDIATRIC BLOOD & CANCER, 2009, 52 (07) : 767 - 771
  • [46] The effects of delayed imatinib mesylate treatment on outcome in patients with GIST.
    Kozaric, Amina Kurtovic
    Kugic, Amina
    Kurtovic, Azra
    Beslija, Semir
    Ceric, Timur
    Pasic, Anes
    Vranic, Semir
    Kozaric, Mirza
    Kopric, Dijana
    Iljazovic, Ermina
    Baruscia, Jelena Todorovic
    Ibisevic, Nermina
    Kurtovic, Sabira
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] Second Primary Malignancy in Patients with Hypopharyngeal Carcinoma: A SEER-Based Study
    Guo, Liqing
    Fu, Yanpeng
    Miao, Chunyu
    Wu, Shuhong
    Zhu, Yaqiong
    Liu, Yuehui
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2021, 14 : 8847 - 8861
  • [48] Apoptotic and anti-vascular activity of imatinib in GIST patients.
    Trent, JC
    Choi, H
    Hunt, K
    Macapinlac, H
    McConkey, D
    Charnsangravej, C
    Abbruzzese, J
    Benjamin, RS
    Davis, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 816S - 816S
  • [49] Use of Hypolipidemic Drugs and the Risk of Second Primary Malignancy in Colorectal Cancer Patients
    Halamkova, Jana
    Bohovicova, Lucia
    Pehalova, Lucie
    Gonec, Roman
    Stanek, Teodor
    Kazda, Tomas
    Moukova, Lucie
    Krakorova, Dagmar Adamkova
    Kozakova, Sarka
    Svoboda, Marek
    Demlova, Regina
    Kiss, Igor
    CANCERS, 2022, 14 (07)
  • [50] Variable Risk of Second Primary Malignancy In Multiple Myeloma Patients of Different Ethnicities
    Razavi, Pedram
    Patel, Gaurav
    Chanan-Khan, Asher
    Ailawadhi, Sikander
    BLOOD, 2011, 118 (21) : 311 - 312
12345